
Opinion|Videos|August 14, 2024
Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS
Drs Koprivnikar and Chedid highlight prognostic scoring systems in MDS.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- When making treatment decisions for lower-risk MDS patients, how do you incorporate prognostic scoring systems like IPSS-R and IPSS-M into your decision-making process?
- Please elaborate on how these scoring systems influence your choice between luspatercept and other available therapies for managing anemia in these patients?
- Please discuss the how mutational burden impacts response and duration of response in the COMMANDS trial.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5






























